<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Pharmaceutical <z:chebi fb="4" ids="48705">agonists</z:chebi> of peroxisome proliferator-activated receptors (PPARs) are widely used in the management of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, chiefly as <z:chebi fb="23" ids="18059">lipid</z:chebi>-lowering agents and oral hypoglycaemic agents </plain></SENT>
<SENT sid="1" pm="."><plain>Although most of the focus has been placed on their cardiovascular effects, both positive and negative, these agents also have significant renoprotective actions in the diabetic kidney </plain></SENT>
<SENT sid="2" pm="."><plain>Over and above action on metabolic control and effects on blood pressure, PPAR <z:chebi fb="4" ids="48705">agonists</z:chebi> also appear to have independent effects on a number of critical pathways that are implicated in the development and progression of <z:e sem="disease" ids="C0011881" disease_type="Disease or Syndrome" abbrv="">diabetic kidney disease</z:e>, including <z:mp ids='MP_0003674'>oxidative stress</z:mp>, <z:mp ids='MP_0001845'>inflammation</z:mp>, <z:mpath ids='MPATH_159'>hypertrophy</z:mpath>, and podocyte function </plain></SENT>
<SENT sid="3" pm="."><plain>This review will examine these direct and indirect actions of PPAR <z:chebi fb="4" ids="48705">agonists</z:chebi> in the diabetic kidney and explore recent findings of clinical trials of PPAR <z:chebi fb="4" ids="48705">agonists</z:chebi> in patients with <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>